Stanton Marshall S. 4
4 · ARTIVION, INC. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
ARTIVION, INC.AORT
Stanton Marshall S.
SVP, Clinical & MD Affair
Transactions
- Award
Common Stock
[F1]2026-03-02+21,838→ 62,246 total - Sale
Common Stock
[F2]2026-03-03$37.78/sh−2,149$81,180→ 60,097 total
Footnotes (2)
- [F1]Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date.
- [F2]These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
Signature
/s/ Marshall Stanton|2026-03-04